Haemostasis January 2025 Journal Club

Keep informed about evolving science and clinical practice with our January 2025 compilation of the latest studies, guidelines, and perspectives in haemostasis.

PERSPECTIVES & REVIEWS

• Albert CM. Oral anticoagulation in device patients with atrial high-rate episodes: Shared decision-making after ARTESIA and NOAH-AFNET-6. Circulation. 2024;150(18):1398-1400. doi:10.1161/CIRCULATIONAHA.124.068018
• Bos MHA, van Diest RE, Monroe DM. Blood coagulation factor IX: structural insights impacting hemophilia B therapy. Blood. 2024;144(21):2198-2210. doi:10.1182/blood.2023023276
• Das K, Rao LVM. Coagulation protease-induced extracellular vesicles: their potential effects on coagulation and inflammation. J Thromb Haemost. 2024;22(11):2976-2990. doi:10.1016/j.jtha.2024.07.022
• Furniss JA, Tarassova N, Poole AW. Platelet generation in vivo and in vitro. Blood. 2024;144(22):2283-2294. doi:10.1182/blood.2024024601
• Green D. Hematology products from snake venoms. Thromb Res. 2025;245:109215. doi:10.1016/j.thromres.2024.109215
• Jobe SM. Antiplatelet therapy: the clot thickens. Blood. 2024;144(24):2471-2472. doi:10.1182/blood.2024027208
• Landi A, Gorog DA, Valgimigli M. Swinging pendulum between risks and benefits of antiplatelet agents: A call for consistency in the interpretation of evidence and guideline recommendations. Circulation. 2025;151(2):126-128. doi:10.1161/CIRCULATIONAHA.124.070797
• Lenting PJ, Denis CV, Christophe OD. How unique structural adaptations support and coordinate the complex function of von Willebrand factor. Blood. 2024;144(21):2174-2184. doi:10.1182/blood.2023023277
• Mackman N, Sachetto ATA. Challenges with measuring tissue factor antigen and activity in human plasma. Blood VTH 2024;1(4):100022.  doi:10.1016/j.bvth.2024.100022
• O’Donnell JS, Baker RI, Atiq F. Low von Willebrand factor-unraveling an enigma wrapped in a conundrum. J Thromb Haemost. 2024;22(12):3383-3388. doi:10.1016/j.jtha.2024.08.015
• Pryzdial GEL, Perrier JR, Rashid MU, et al. Viral coagulation: pushing the envelope. J Thromb Haemost. 2024;22(12):3366-3382. doi:10.1016/j.jtha.2024.08.014
• Samelson-Jones BJ, Doshi BS, George LA. Coagulation factor VIII: biological basis of emerging hemophilia A therapies. Blood. 2024;144(21):2185-2197. doi:10.1182/blood.2023023275
• Sandset EC, de Sousa DA. Optimal anticoagulation timing after ischaemic stroke in patients with atrial fibrillation. Lancet. 2024;404(10464):1702 – 1703. doi:10.1016/S0140-6736(24)02259-1

CLINICAL TRIALS

• Carvalho PE, Gewehr DM, Nascimento BR, et al. Short-term dual antiplatelet therapy after drug-eluting stenting in patients with acute coronary syndromes: A systematic review and network meta-analysis. JAMA Cardiol. 2024;9(12):1094-1105. doi:10.1001/jamacardio.2024.3216
• Ceulemans A, Barakzie A, Spronk HMH, et al. Association between coagulation activity and clinical and imaging outcomes in acute ischemic stroke patients – A sub-study of the MR CLEAN NO-IV trial. Thromb Res. 2025;245:109212. doi:10.1016/j.thromres.2024.109212
• Hupperetz RD, Iding AFJ, van Laanen J, et al. Patency and reflux in relation to postthrombotic syndrome: a subanalysis of the Ultrasound-Accelerated Catheter-Directed Thrombolysis Versus Anticoagulation for the Prevention of Post-Thrombotic Syndrome trial. J Thromb Haemost. 2024;22(12):3552-3561. doi:10.1016/j.jtha.2024.08.022
• Ma J, Zhang X, Zhao L, et al. Efficacy and safety of recombinant human thrombopoietin for the treatment of chronic primary immune thrombocytopenia in children and adolescents: A multicentre, randomized, double-blind, placebo-controlled phase III trial. Br J Haematol. 2024;205(6):2403-2413. doi:10.1111/bjh.19761
• Macoviciuc M, Furneri C, Callens L, et al. Anticoagulation stewardship in the ambulatory settings of long-term care and rehabilitation – A multi-centric descriptive pilot study. Thromb Res. 2025;245:109238. doi:10.1016/j.thromres.2024.109238
• Meng X, Li S, Dai H, et al. Tenecteplase vs alteplase for patients with acute ischemic stroke: The ORIGINAL randomized clinical trial. JAMA. 2024;332(17):1437-1445. doi:10.1001/jama.2024.14721
• Verso M, Maraziti G, Vinci A, et al. Clinical and endoscopic findings in patients with acute gastrointestinal bleeding associated with direct oral anticoagulants: Results from a single-center prospective cohort study. Thromb Res. 2025;245:109227. doi:10.1016/j.thromres.2024.109227
• Wahid L, Froess JD, Ortel TL, et al. On-treatment change in D-dimer is associated with differential outcomes among therapeutic dose heparin-treated noncritically Ill patients hospitalized for COVID-19. Arterioscler Thromb Vasc Biol. 2025;45(1):162-164. doi:10.1161/ATVBAHA.124.321108
• Werring DJ, Dehbi HM, Ahmed N, et al. Optimal timing of anticoagulation after acute ischaemic stroke with atrial fibrillation (OPTIMAS): a multicentre, blinded-endpoint, phase 4, randomised controlled trial. Lancet. 2025;404(10464):1731-1741. doi: 10.1016/S0140-6736(24)02802-2

CASE SERIES & RETROSPECTIVE STUDIES

• Appelman EM, Martens ESL, Burger DM, et al. Drug-drug interactions between direct oral anticoagulants and anticancer drugs: A single center daily practice evaluation of the occurrence, prescriber response, and subsequent thrombotic and bleeding complications in the Netherlands. Thromb Res. 2025;245:109232. doi:10.1016/j.thromres.2024.109232
• DeSancho MT, Suvar E, Roberts JC, et al. Hereditary antithrombin deficiency pilot project registry from the American Thrombosis and Hemostasis Network. J Thromb Haemost. 2024;22(11):3183-3190. doi:10.1016/j.jtha.2024.07.026
• Desprez D, Pierre L, Hittinger X, et al. Efficacy and safety of a recombinant von Willebrand factor treatment in acquired von Willebrand syndrome in case of bleeding and surgical procedures. Haemophilia. 2024;30(6):1341-1347. doi:10.1111/hae.15098
• El Beayni N, Lassila R, Lehtinen AE, et al. A case of acquired factor XI deficiency and severe bleeding tendency associated with Streptococcus pyogenes cellulitis. Br J Haematol. 2025;206(1):342-344. doi:10.1111/bjh.19908
• Englisch C, Vostatek R, Schramm T, et al. Association of clonal haematopoiesis with recurrent venous thromboembolism: A case-control study. Br J Haematol. 2025;206(1):263-271. doi:10.1111/bjh.19871
• García-Diego DA, Badia X, Benítez-Hidalgo O, et al. Value contribution of etranacogene dezaparvovec gene therapy in moderately severe and severe haemophilia B through multi-criteria decision analysis. Haemophilia. 2024;30(6):1281-1287. doi:10.1111/hae.15096
• Kanack AJ, Leung N, Padmanabhan A. Diagnostic Complexity in Monoclonal Gammopathy of Thrombotic Significance. N Engl J Med. 2024;391(20):1961-1963. doi:10.1056/NEJMc2409428
• Kishi D, Nishikubo M, Shimomura Y, et al. Clinical characteristics and outcomes of acquired hemophilia A before and after emicizumab approval in Japan. Blood VTH 2024;1(4):100027. doi:10.1016/j.bvth.2024.100027
• Koami H, Sakamoto Y, Hirota Y, et al. Effect of hypofibrinolysis on clinical outcomes of patients with septic disseminated intravascular coagulation. Thromb Res. 2025;245:109235. doi:10.1016/j.thromres.2024.109235
• Krahforst A, Yadegari H, Pavlova A, et al. Unravelling the spectrum of von Willebrand factor variants in quantitative von Willebrand disease: results from a German cohort study. J Thromb Haemost. 2024;22(11):3010-3034. doi:10.1016/j.jtha.2024.06.026
• Kwawegen CB, Atiq F, Endenburg D, et al. Genetic variants, thrombocytopenia, and clinical phenotype of type 2B von Willebrand disease: a median 16-year follow-up study. J Thromb Haemost. 2024;22(12):3460-3472. doi:10.1016/j.jtha.2024.08.028
• Martens ESL, Becker D, Abele C, et al. Understanding European patterns of deprescribing antithrombotic medication during end-of-life care in patients with cancer. Thromb Res. 2025;245:109205. doi:10.1016/j.thromres.2024.109205
• Mathur A, Cairns A, Watson HG, et al. Is interrupting anticoagulation for thrombosis risk stratification safe? Blood VTH 2024;1(4):100028. doi:10.1016/j.bvth.2024.100028
• Milling TJ, Voronov A, Schmidt DS, et al. Long-Term Safety of a Four-Factor Prothrombin Complex Concentrate (Kcentra®/Beriplex® P/N): An Updated Pharmacovigilance Review. Thromb Haemost. 2025;125(1):46-57. doi:10.1055/s-0044-1788305
• Patil T, Ali S, Eppes D, et al. Evaluating the safety and effectiveness of direct oral anticoagulants compared with warfarin in very elderly patients with atrial fibrillation with and without low bodyweight. J Thromb Haemost. 2024;22(11):3107-3124. doi:10.1016/j.jtha.2024.07.011
• Prandoni P, Bilora F, Pesavento R, et al. DOAC Score for prediction of major bleeding in patients with venous thromboembolism: Findings from the RIETE registry. Thromb Res. 2025;245:109226. doi:10.1016/j.thromres.2024.109226
• Qiu C, Huang L, Wang Y, et al. Anticoagulation plus antiplatelet therapy versus anticoagulation alone following iliac vein stent implantation in acute and subacute deep vein thrombosis: A multicenter study with propensity score matching. Thromb Res. 2024;244:109197. doi:10.1016/j.thromres.2024.109197
• Simioni P, Cipriano A, D’Angelo A, et al. The efficacy and safety of andexanet alfa in the treatment of anticoagulation-related major bleedings: An Italian perspective. Thromb Res. 2025;245:109241. doi:10.1016/j.thromres.2024.109241
• Sueta D, Yamashita Y, Morimoto T, et al. Edoxaban, Rivaroxaban, or Apixaban for Cancer-Associated Venous Thromboembolism in the Real World: Insights from the COMMAND VTE Registry-2. Thromb Haemost. 2024;124(11):1013-1023. doi:10.1055/a-2316-5269
• Vandenhazel HL, Wilson AS, Ye X, et al. Direct oral anticoagulant prescribing trends for venous thromboembolism among adult patients with obesity at University of Utah Health. Thromb Res. 2025;245:109216. doi:10.1016/j.thromres.2024.109216
• Vaismann S, Stein N, Dizengoff L, et al. Risk of Major Bleeding with Antiplatelet and/or Anticoagulation Therapy in Inherited Factor XI Deficiency: Insights from Real-World Observations. Thromb Haemost. 2025;125(1):82-84. doi:10.1055/a-2347-4338
• Villas JMC, López MR, Tovar JC, et al. Suitability and readiness assessment of organizational resources for the implementation of gene therapy in hemophilia in Spain and Portugal: A survey-based study. Thromb Res. 2024;244:109180. doi:10.1016/j.thromres.2024.10918
• Weisinger J, Bouzid R, Ranta D, et al. Efficacy and safety of daratumumab in multiresistant immune-mediated thrombotic thrombocytopenic purpura. Br J Haematol. 2024;205(5):1951-1958. doi:10.1111/bjh.19752
• Yamakawa K, Ohbe H, Mochizuki K, et al. Time trends of outcome and treatment options for disseminated intravascular coagulation from 2010 to 2021 in Japan: A nationwide observational study. Thromb Res. 2024;244:109206. doi:10.1016/j.thromres.2024.109206
• Yang D, Deng J, Huang S, et al. Clinical features, outcomes, and anticoagulant strategies in lung cancer-associated isolated distal deep vein thrombosis. Thromb Res. 2024;244:109193. doi:10.1016/j.thromres.2024.109193
• Youkhana K, Batsuli G, Acharya S, et al. Real-world effectiveness of eptacog beta in patients with haemophilia and inhibitors: A multi-institutional case series. Haemophilia. 2024;30(6):1321-1331. doi:10.1111/hae.15094
• Zighed H, Huguenin Y, Blanc L, et al. Lupus-associated hypoprothrombinemia syndrome in children: Differences between post-infectious and autoimmune forms. Thromb Res. 2025;245:109231. doi:10.1016/j.thromres.2024.109231

RESEARCH

• Chabata CV, Yu H, Ke L, et al. Andexanet alfa-associated heparin resistance in cardiac surgery: Mechanism and in vitro perspectives. Arterioscler Thromb Vasc Biol. 2025;45(1):144-156. doi:10.1161/ATVBAHA.124.321650
• Feige T, Bosbach A, Krott KJ, et al. GP VI-mediated platelet activation and procoagulant activity aggravate inflammation and aortic wall remodeling in abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol. 2024;44(11):2294-2317. doi:10.1161/ATVBAHA.123.320615
• Graus JG, Prückler M, Bergmeister H, et al. Prethrombin-1 as a Drug Substance Promoting Hemostasis with Reduced Risk of Thrombosis. Thromb Haemost. 2025;125(1):36-45. doi:10.1055/s-0044-1787720
• Kaiser R, Dewender R, Mulkers M, et al. Procoagulant platelet activation promotes venous thrombosis. Blood. 2024;144(24):2546-2553. doi:10.1182/blood.2024025476
• Leonard J, Kepplinger D, Torres E, et al. Comparative analysis of Lox-1 and CD36 expression in human platelets and on circulating microparticles during ARDS-induced coagulopathy. Thromb Res. 2024;244:109202. doi:10.1016/j.thromres.2024.109202
• Li Y, Jiang H, Li X, et al. Platelet-specific deletion of TGF-β1 impairs septic thrombosis in mice-Brief Report. Arterioscler Thromb Vasc Biol. 2025;45(1):136-143. doi:10.1161/ATVBAHA.124.322029
• Liu Z, Li X, Chen M, et al. Heparin-binding protein and sepsis-induced coagulopathy: Modulation of coagulation and fibrinolysis via the TGF-β signalling pathway. Thromb Res. 2024;244:109176. doi:10.1016/j.thromres.2024.109176
• Nakajima, Y., Ogiwara, K., Inaba, et al. NXT007 does not interfere with the anticoagulant effects on tissue factor pathway inhibitor. Haemophilia. 2024;30:1435-1439. doi:10.1111/hae.15106
• Pelesz A, Rafa-Zablocka K, Kaczara P, et al. Protein disulfide isomerase 1 (PDIA1) regulates platelet-derived extracellular vesicle release. Thromb Res. 2025;245:109209. doi:10.1016/j.thromres.2024.109209
• Shen C, Mackeigan DT, Shoara AA, et al. Novel GPIb-independent platelet aggregation induced by botrocetin: implications for diagnosis and antithrombotic therapy. J Thromb Haemost. 2024;22(11):3249-3265. doi:10.1016/j.jtha.2024.06.030
• Shimizu K, Nakajima Y, Takami E, et al. Additional Factor X Enhances Emicizumab-Driven Coagulation Function in Patients with Hemophilia A and Hemophilia A Mice. Thromb Haemost. 2025;125(1):21-32. doi:10.1055/a-2315-8199
• Schönichen C, Sun S, Middelveld H, et al. Functionally distinct anticoagulant mechanisms of endothelial cells. Thromb Res. 2024;244:109208. doi:10.1016/j.thromres.2024.109208
• Thaler J, Tripisciano C, Kraemmer D, et al. Saliva of persons with hemophilia A triggers coagulation via extrinsic tenase complexes. Blood. 2024;144(25):2666-2677. doi:10.1182/blood.2024025093
• Vir P, Gunasekera D, Dorjbal B, et al. Lack of factor VIII detection in humans and dogs with an intron 22 inversion challenges hypothesis regarding inhibitor risk. J Thromb Haemost. 2024;22(12):3415-3430. doi:10.1016/j.jtha.2024.08.007
• Wu X, Li L, Lu Z, et al. Heterozygous Prothrombin Mutation-Associated Thrombophilia. Thromb Haemost. 2025;125(1):69-81. doi:10.1055/a-2350-8338
• Xue R, Li M, Zhang G, et al. GSDME-mediated pyroptosis contributes to chemotherapy-induced platelet hyperactivity and thrombotic potential. Blood. 2024;144(25):2652-2665. doi:10.1182/blood.2023023179

METHODS

• Ajzenberg N, Longrois D, Faille D, et al. Sensitivity and specificity of strategies to identify patients with hemostasis abnormalities leading to an increased risk of bleeding before scheduled intervention: the Hemorisk study. J Thromb Haemost. 2024;22(11):3048-3058. doi:10.1016/j.jtha.2024.07.024
• Bourguignon A, Mathews N, Tasneem S, et al. Rapid diagnosis of coagulopathies from vitamin K deficiency in a consecutive case cohort evaluated by comparative assessment of factor II by 1-stage assays with prothrombin time vs Ecarin reagents. J Thromb Haemost. 2024;22(11):3059-3069. doi:10.1016/j.jtha.2024.08.002
• Bruzek S, Betensky M, Sochet AA, et al. Methods, precision, and analytical sensitivity of a novel low-plasma-volume assay of fibrinolytic capacity utilizing the euglobulin fraction. Int J Lab Hematol. 2024;46(6):1092-1100. doi:10.1111/ijlh.14340
• Clearfield E, Kim B, Ford S, et al. A core outcome set for prophylaxis and perioperative treatment of von Willebrand disease: The coreVWD initiative. Haemophilia. 2024;30(6):1357-1365. doi:10.1111/hae.15122
• Cole MA, Ranjan N, Gerber GF, et al. Complement biosensors identify a classical pathway stimulus in complement-mediated thrombotic microangiopathy. Blood. 2024;144(24):2528-2545. doi:10.1182/blood.2024025850
• De Smet D, Hemelsoet D, De Herdt V, et al. Heparin-calibrated chromogenic anti-Xa assay for the detection of threshold-levels of direct oral anticoagulants. Int J Lab Hematol. 2024;46(6):1136-1139. doi:10.1111/ijlh.14357
• Duchez V, Ternisien C, Guery EA, et al. Cross-reactivity of human anti-FVIII antibodies to porcine rFVIII: French field study to validate the modified Nijmegen method. Int J Lab Hematol. 2024;46(6):1118-1122. doi:10.1111/ijlh.14331
• Hardy M, Douxfils J, Xhaet O, et al. Development and validation of an in vitro model to study thrombin generation on the surface of catheters in platelet-poor and platelet-rich plasma. Thromb Res. 2024;244:109194. doi:10.1016/j.thromres.2024.109194
• Jani E, Bozzola M, Zagler EM, et al. Is the combination of two automated rapid assays for diagnosis of heparin-induced thrombocytopenia necessary? Blood Coagul Fibrinolysis. 2024;35(8):362-364. doi:10.1097/MBC.0000000000001327
• Maruyama K, Kokame K. Development of an assay using a modified coagulation factor V to measure protein S activity. J Thromb Haemost. 2024;22(12):3510-3520. doi:10.1016/j.jtha.2024.08.010
• Seyve L, Prigent JB, Lo Presti C, et al. Effect of emicizumab on activated clotting time performed on i-STAT Alinity analyzer. Int J Lab Hematol. 2024;46(6):1132-1135. doi:10.1111/ijlh.14343
• Shimomura D, Kumano O, Ueda K, et al. New method to differentiate between lupus anticoagulants, progressive coagulation inhibitors and coagulation factor deficiencies in the mixing tests. Int J Lab Hematol. 2024;46(6):1084-1091. doi:10.1111/ijlh.14289
• Sin CF, Wong KP, Siu CW, et al. Utilization of international normalized ratio-derived formula to predict plasma rivaroxaban level-Validation study and real-world experience. Int J Lab Hematol. 2024;46(6):1101-1108. doi:10.1111/ijlh.14347
• Thiriet A, Poindron V, Sattler L, et al. Evaluation of an integrated activated partial thromboplastin time (Cephen LS/Cephen) for the detection of lupus anticoagulant. Int J Lab Hematol. 2024;46(6):1109-1117. doi:10.1111/ijlh.14349